CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 193 enrolled
Drug / intervention
Phentermine-Topiramate +3 moredrug
Likely dose
Multiple doses tested: phentermine-topiramate ER 7.5/46 mg oral daily, liraglutide 3 mg subcutaneous daily, naltrexone/bupropion ER 32/360 mg oral daily, or phentermine 15-37.5 mg oral dailyAI-extracted
Key inclusion· 2
  • ✓Adults with BMI >30 kg/m² and otherwise healthy with no unstable psychiatric disease and controlled comorbidities
  • ✓Men or women; women of childbearing potential must have negative pregnancy test within 48 hours of enrollment
Key exclusion· 4
  • ✕Prior abdominal bariatric surgery
  • ✕Chronic gastrointestinal disease or systemic disease affecting GI motility, or medications altering GI motility, appetite, or absorption (e.g., orlistat) within last 6 months
  • ✕Significant untreated psychiatric dysfunction: anxiety/depression score >11 on HAD or eating/weight pattern disorders (binge eating, bulimia) on QEWP
  • ✕Hypersensitivity to any study medication

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03374956
NCT03374956Phase 3Completed
CompareCT.gov

Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial

Mayo Clinic·interventional·Posted Dec 15, 2017·Updated Jul 18, 2023

In Brief

A Phase 3 clinical trial evaluating Phentermine-Topiramate, Liraglutide, and 2 other interventions for Obesity. Completed, enrolled 193 participants across 1 site.

Detailed Summary

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 15, 2017
Enrollment StartDec 11, 2017
Primary CompletionMay 26, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.5 years ago

Interventions

Phentermine-Topiramatedrug

Extended Release at dose of 7.5/46 mg oral daily

Liraglutidedrug

dose of 3 mg subcutaneous daily

Naltrexone/bupropiondrug

Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)

Phenterminedrug

15-37.5 mg oral daily